ALZ4500 | Alzheimer's Research and Treatment Center

Lecanemab in Early Alzheimer’s Disease.

Nov 29, 2022 | Article

Dr. David Watson of ARTC is one of the primary author’s of this article on Lecanemab and Alzheimer’s Disease. The accumulation of soluble and insoluble aggregated amyloid-beta (Aβ) may initiate or potentiate pathologic processes in Alzheimer’s disease....

Positive Topline Results from the Clinical Trial of Lecanemab.

Nov 11, 2022 | Press Release

In September 2022, Eisai Co. and Biogen Inc. announced very positive topline results from the clinical trial of Lecanemab, an investigational treatment for mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s Disease. Eisai will be presenting the...

A Breakthrough in Alzheimer’s Disease.

Sep 28, 2022 | Press Release

Dr. Watson at ARTC is the world’s leading investigator for the Lecanemab compound. On September 27, 2022 Eisai Co.,LTD and Biogen Inc. released the following statement. Read Press...

Lecanemab in Early Alzheimer’s Disease.

Positive Topline Results from the Clinical Trial of Lecanemab.

A Breakthrough in Alzheimer’s Disease.

Recent Posts